Rep. Steve Cohen Sells Emergent BioSolutions Inc. (NYSE:EBS) Stock

Representative Steve Cohen (D-Tennessee) recently sold shares of Emergent BioSolutions Inc. NYSE: EBS. In a filing disclosed on January 10th, the Representative disclosed that they had sold between $1,001 and $15,000 in Emergent BioSolutions stock on December 11th. The trade occurred in the Representative's "STEPHENS SEP IRA" account.

Representative Steve Cohen also recently made the following trade(s):

• Sold $15,001 - $50,000 in shares of Host Hotels & Resorts NASDAQ: HST on 12/11/2024.

Emergent BioSolutions Stock Performance

NYSE EBS traded up $0.10 during trading hours on Wednesday, reaching $9.46. The stock had a trading volume of 834,751 shares, compared to its average volume of 988,783. Emergent BioSolutions Inc. has a 52-week low of $1.42 and a 52-week high of $15.10. The stock has a fifty day moving average of $9.37 and a 200 day moving average of $9.18. The company has a debt-to-equity ratio of 1.30, a quick ratio of 1.47 and a current ratio of 2.88. The stock has a market cap of $512.58 million, a P/E ratio of -2.31 and a beta of 1.60.

Wall Street Analyst Weigh In

EBS has been the subject of several recent research reports. Benchmark raised their target price on shares of Emergent BioSolutions from $8.00 to $12.00 and gave the stock a "buy" rating in a report on Thursday, November 7th. HC Wainwright reissued a "buy" rating and issued a $15.00 price objective on shares of Emergent BioSolutions in a report on Friday, January 10th. Finally, StockNews.com raised Emergent BioSolutions from a "hold" rating to a "buy" rating in a report on Tuesday.

Institutional Trading of Emergent BioSolutions

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Meeder Asset Management Inc. purchased a new stake in shares of Emergent BioSolutions during the 2nd quarter worth about $41,000. Stifel Financial Corp acquired a new position in Emergent BioSolutions in the 3rd quarter worth about $96,000. FORA Capital LLC purchased a new position in Emergent BioSolutions during the third quarter worth approximately $103,000. Vanguard Personalized Indexing Management LLC acquired a new stake in Emergent BioSolutions in the second quarter valued at approximately $93,000. Finally, Morse Asset Management Inc purchased a new stake in shares of Emergent BioSolutions in the second quarter valued at approximately $97,000. Institutional investors and hedge funds own 78.40% of the company's stock.

About Representative Cohen

Steve Cohen (Democratic Party) is a member of the U.S. House, representing Tennessee's 9th Congressional District. He assumed office on January 3, 2007. His current term ends on January 3, 2025. Cohen (Democratic Party) is running for re-election to the U.S. House to represent Tennessee's 9th Congressional District. He declared candidacy for the Democratic primary scheduled on August 1, 2024. He represented District 30 of the Tennessee State Senate from 1983-2006. As a child, Cohen contracted polio. Cohen filed to run for his first elected office the same day that he first registered to vote. Cohen earned a bachelor's degree from Vanderbilt and a J.D. from the University of Memphis School of Law. Prior to his election to the U.S. House, Cohen was a member of the Tennessee State Senate.

About Emergent BioSolutions

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.